

Office of the Chief Counsel Food and Drug Administration 5600 Fishers Lane, GCF-1 Rockville, MD 20857

Carl Malamud President & CEO Public.Resource.Org 1005 Gravenstein Highway North Sebastopol, California 95472

Re: FOIA Request 2009-4071

Dear Mr. Malamud:

As requested in your Freedom of Information request dated May 20, 2009, we are enclosing material from the Office of the Chief Counsel that responds to your request.

The following charges for this request to date may be included in a monthly invoice:

Reproduction	Search	Review	Fiche	Other	Total
2.00	0	0	0	0	\$2.00

The above total may not reflect final charges for this request. Please do not send payment unless you receive an invoice.

All communications concerning this request should be identified with the reference number above and addressed as follows:

Food and Drug Administration Division of Freedom of Information, HFI-35 5600 Fishers Lane, Room 6-30 Rockville, MD 20857 Carl Malamud Page 2

Sincerely yours,

Ann H. Wion Deputy Chief Counsel for Program Review

Enclosure

HFI-35 cc:

Reg.# 1052597 .



DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration



1. IAG NO. (FDA)	2. TYPE OF AGREEMEN	Ť		3. MODIFICATION NO.
224-95-8003	New Mod	Administrative	No Cost Ext.	17
4. TITLE OF PROJECT	<u> </u>			5. SECURITY CLAUSE APPLIES
Westlaw and LEXIS On-Line Legal Research	h Services			Yes (See attached) No
6. DESCRIPTION OF WORK - ATTACHED			7. AMOUNT	
Attached		1	\$74,096.00	
8. NAME AND ADDRESS OF PARTICIPATING FEDER.	AL AGENCY	9. LIAISON TO PAR	RTICIPATING FEDERA	
OS/Office of the General Counsel		a. Name		b. Phone No. (202) 619-0190
330 Independence Ave., SW, Room 700E Washington, DC 20201		Susan M. Pana	asik	d. FAX No.
10. NAME AND ADDRESS OF PARTICIPATING FDA U	NIT	.1	ARTICIPATING FDA UN	NIT
FDA/Office of Chief Counsel		a. Name		b. Phone No.
5600 Fishers Lane, Rm. 6A05		Kelley Biser		(301) 827-1167
Rockville, MD 20857	•	c. E mail:		d. FAX No.
12. PERIOD OF AGREEMENT FROM:	October 1, 2008		тняоисн: Septe	ember 30, 2009
This agreement may be terminated by elt FDA, FDA will retain title for any equipmen				
13. AUTHORITY (FDA) Economy Act approved June 30, 1932, as amen	ded by 31 U.S.C. 1535			
Section 301 of the Public Health Service Act (42	•			
Other (specify) 14. AUTHORITY (Other Agency)				
THE NOTITIONALL (Guidi Agolloy)				•
15, FDA FUNDING INFORMATION				
Increase from \$by \$	74,096.00 to	\$74,096.00	·	
Decrease from \$ by \$	to	\$	io	•
16. Administrative billing requirements will comply with G	AO Policy and Procedures,	Title 7, Section 8.4		
Billing: X IPAC system FD.	A ALC 75060099 Other Age	ncy ALC		•
SF 1080 - FDA A	accounting (HFA-120) 5600	Fishers Lane, Rockville	a, MD 20857	
17. PARTICIPATING AGENCY FUNDING INFORMATIO	- ·			1
Note: a. Legal authority for the acquisition of suppl b. This action does not conflict with any other	ies/services exists within you	ur agency.	g provided to the PDA.	,
				•
			<u>*</u>	<u> </u>
18. PARTICIPATING AGENCY IS				
✓ Required to sign	Not required to sign	0		\wedge
19. FDA ACCEPTANCE		20. PARTICIPATING	AGENCY ACCEPTAN	IGE Dunil
NAME:		NAME: Susan M	. Panasik	· Tumuc
		<i>f</i>	4	
TITLE:		TITLE: Legal Info	ormation Manager	
		11	129/10	
DATE:		DATE: //	1-1100	
FDA 3443 (1/02)				PSC Modis Ans (301) 443-1090 EF

INTERAGENCY AGREEMENT

BETWEEN THE

FOOD AND DRUG ADMINISTRATION (FDA) AND THE

OFFICE OF THE GENERAL COUNSEL (OGC) DEPARTMENT OF HEALTH AND HUMAN SERVICES

This agreement sets forth the terms under which the Food and Drug Administration (FDA) is to reimburse the Office of the General Counsel (OGC) for WESTLAW, LEXISNEXIS, and PACER usage. In addition, this agreement authorizes the transfer of funds to the OGC when certain economies can be realized through joint purchases of publications and subscriptions.

I. PURPOSE

The OGC will fund and manage WESTLAW and LEXISNEXIS, BNA, and PACER contracts on behalf of the Office of the General Counsel Food and Drug Division (FDD). The FDA will transfer funds to cover FDD's portion of the charges for use of these online services. The charges will consist of two components: a proportion of OGC's fixed rate charges for FY 2009 for each service plus a reimbursement of any FDD usage not covered under the fixed rate agreements. Additional monies will fund FDD's use of the PACER system for tracking the status of court cases and provision of other services to the FDD library. Finally, FDA will reimburse OGC for any expenditures made for the FDD in order to obtain savings through joint purchases of publications and subscriptions.

II. PERIOD OF PERFORMANCE

This agreement covers the period October 1, 2008 to September 30, 2009.

III. AUTHORITY

This agreement is authorized by 31 U.S.C. 1535 (the Economy Act).

IV. FINANCIAL PROVISIONS

FDA will transfer the sum of Seventy-Four Thousand Ninety-Six Dollars (\$74,096.00) to the OGC as follows:

- 1.) The sum of Forty-Eight Thousand Dollars (\$48,000.00) will cover the FDD share of the fixed rate contracts with WESTLAW for FY 2009.
- 2.) The sum of Twenty-One Thousand Six Hundred Dollars (\$21,600.00) will cover the FDD share of the fixed rate contracts with LEXISNEXIS for FY 2009.
- 3.) The sum of One Thousand Dollars (\$1,000.00) will be used for non-fixed rate usage. The OGC may request additional funds for non-fixed rate usage if usage exceeds this amount.
- 4.) The sum of Two Thousand Dollars (\$2,000.00) for OGC's projected PACER use by FDA personnel for the period of the agreement.
- 5.) The sum of One Thousand Five Hundred Dollars (\$1,500.00) for BNA's U.S. Law Week subscription.

FDA agrees that the transfer of monies for online services and the library services will take place within thirty days of the date of the last signature affixed hereto.

From: FDA

To: OGC

Appropriation: 7590600 CAN : 9-6993830 Object Class : 25308

Object Class : 25308 Amount : \$74,096.00 D&B Number : 927645523 ALC : 75-06-0099 Appropriation: 7590120 CAN : 9-1990598 Object Class : 25308 Amount : \$74,096.00

D&B Number : 803192033 ALC : 75030030

V. APPROVAL AND ACCEPTANCE

Approved and accepted for FDA

By: Joseph/T. Swith Executive Officer

Date: 10/29/08

Approved and accepted for the Office of the deneral Counsel

By:
Paul R. Johnson
Chief Operating Officer

Date: 1/2/00

Entered into it 3/4/08 TAG advicted : 94150067AP08000 leg# = 1040838

FY08



DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration



			a Manufatrian No.
1. IAG NO. (FDA) 224-95-8003	2. TYPE OF AGREEMENT New Mod	Administrative No Cost Ext.	3. MODIFICATION NO. 16
4. TITLE OF PROJECT Westlaw and LEXIS On-Line Legal Resea	rch Services		5. SECURITY CLAUSE APPLIES Yes (See attached) No
DESCRIPTION OF WORK - ATTACHED Attached		7. AMOUNT \$68,750.0	
THE AND ADDRESS OF PARTICIPATING SERVE	DAL ACENCY	9. LIAISON TO PARTICIPATING FE	DERAL AGENCY
B. NAME AND ADDRESS OF PARTICIPATING FEDER OS/Office of the General Counsel	WE AGENCT	a. Name	b. Phone No.
330 Independence Ave., SW, Room 700E		Susan M. Panasik	(202) 619 - 0190
Washington, DC 20201		c. E mail:	d. FAX No.
10. NAME AND ADDRESS OF PARTICIPATING FDA	TIMIT	11, LIAISON TO PARTICIPATING FI	DA UNIT
FDA/Office of Chief Counsel	CIVII	a. Name	b. Phone No.
5600 Fishers Lane		Kelley Biser	(301) 827 - 1167
Rockville, MD 20857	'	c. E mail:	d. FAX No.
12. PERIOD OF AGREEMENT			
12. PERIOD OF AGREEMENT FROM	: October 1, 2007	тняоидн: Septe	ember 30, 200 B
This agreement may be terminated by eit FDA, FDA will retain title for any equipme	her party upon a thirty dent procured under this a	ay advance written notice. If this Agragreement, unless otherwise justified	eement is funded by the in the statement of work.
Section 301 of the Public Health Service Act (42) Other (specify) AUTHORITY (Other Agency)	2 USC 241)		·
15. FDA FUNDING INFORMATION			<u></u>
☐ Increase from \$	by \$ 68,750.00	to \$ 68,750.00	
Decrease from \$	by \$	to \$ 0.00	
16. Administrative billing requirements will comply with G	SAO Policy and Procedures, Til	le 7, Section 8.4	
⊠ Billing: X	IPAC system FDA ALC 7506	50099 Other Agency ALC	
П		HFA-120) 5600 Fishers Lane, Rockville, MD 20	857
17. PARTICIPATING AGENCY FUNDING INFORMATION		·	
Note: a. Legal authority for the acquisition of supple. b. This action does not conflict with any other	olies/services exists within your	agency.	
8. PARTICIPATING AGENCY IS			
Required to sign Not re	equired to sign	·	•
9. FDA ACCEPTANCE		20. PARTICIPATING AGENCY ACCEPTANCE	DE
NAME:		NAME: Susan M. Panasik	
TITLE:		TITLE: Legal Information Manag	ger, OLR
DATE:		DATE: 3/4/	08

INTERAGENCY AGREEMENT

BETWEEN THE

FOOD AND DRUG ADMINISTRATION (FDA) AND THE

OFFICE OF THE GENERAL COUNSEL (OGC) DEPARTMENT OF HEALTH AND HUMAN SERVICES

This agreement sets forth the terms under which the Food and Drug Administration (FDA) is to reimburse the Office of the General Counsel (OGC) for WESTLAW, LEXISNEXIS, and PACER usage. In addition, this agreement authorizes the transfer of funds to the OGC when certain economies can be realized through joint purchases of publications and subscriptions.

I. PURPOSE

The OGC will fund and manage WESTLAW, LEXISNEXIS, and BNA contracts on behalf of the Office of the General Counsel Food and Drug Division (FDD). The FDA will transfer funds to cover FDD's portion of the charges for use of these online services. The charges will consist of two components: a proportion of OGC's fixed rate charges for FY 2008 for each service plus a reimbursement of any FDD usage not covered under the fixed rate agreements. Additional monies will fund FDD's use of the PACER system for tracking the status of court cases and provision of other services to the FDD library. Finally, FDA will reimburse OGC for any expenditures made for the FDD in order to obtain savings through joint purchases of publications and subscriptions.

II. PERIOD OF PERFORMANCE

This agreement covers the period October 1, 2007 to September 30, 2008.

III. AUTHORITY

This agreement is authorized by 31 U.S.C. 1535 (the Economy Act).

IV. FINANCIAL PROVISIONS

FDA will transfer the sum of Sixty-Eight Thousand Seven Hundred and Fifty 'Dollars (\$68,750.00) to the OGC as follows:

- 1.) The sum of Fifty Thousand Dollars (\$50,000.00) will cover the FDD share of the fixed rate contracts with WESTLAW for FY 2008.
- 1.) The sum of Fourteen Thousand Four Hundred Dollars (\$14,400.00) will cover the FDD share of the fixed rate contracts with LEXISNEXIS for FY 2008.
- 2.) The sum of One Thousand Dollars (\$1,000.00) will be used for non-fixed rate usage. The OGC may request additional funds for non-fixed rate usage if usage exceeds this amount.
- 3.) The sum of Two Thousand Dollars (\$2,000.00) for OGC's projected PACER use by FDA personnel for the period of the agreement.
- 4) The sum of One Thousand Five Hundred Dollars (\$ 1,350.00) for BNA's U.S. Law Week subscription.

FDA agrees that the transfer of monies for online services and the library services will take place within thirty days of the date of the last signature affixed hereto.

From: FDA

To: <u>OGC</u>

Appropriation: 7580600 : 8-6993830 CAN Object Class: 25308 Amount : \$ 68,750 : 927645523 D&B Number : 75-06-0099 ALC

Appropriation: 7580120 : 8-1990598 CAN Object Class: 25308 Amount : \$68,750

: 75030030

803192033 D&B Number : 112463521

APPROVAL AND ACCEPTANCE <u>v.</u>

> Approved and accepted for FDA

Joseph/T. Smith Executive Officer

Approved and accepted for the Office of the General Counsel

Paul R. Johnson

Chief Operating Officer



DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration



1. IAG NO. (FDA)	2. TYPE OF AGREEME	NT ·		3. MODIFICATION NO.	
224-95-8003	New V Mod	· · ·	No Cost Ext.	15	
1. TITLE OF PROJECT				5. SECURITY CLAUSE APP	PLIES
Westlaw and LEXIS On-Line Legal R	esearch Services		•	Yes (See attached)	No
DESCRIPTION OF WORK - ATTACHED	· · · · · · · · · · · · · · · · · · ·	·	7. AMOUNT		
Inchanged from 04 - Attached		•	\$76,800.00		
. NAME AND ADDRESS OF PARTICIPATING	FEDERAL AGENCY	9. LIAISON TO PA	RTICIPATING FEDERA		
OS/Office of the General Counsel		a. Name	,	b. Phone No.	
330 Independence Ave., SW, Room Vashington, DC 20201	700E	Susan M. Par	nasik 	(202) 619-0190 d. FAX No.	
·		o, E mail:	·		
0. NAME AND ADDRESS OF PARTICIPATIN	IG FDA UNIT	11. LIAISON TO F	ARTICIPATING FDA U	b. Phone No.	
FDA/Office of Chief Counsel	•	.		(301) 827-1167	•
5600 Fishers Lane Rockville, MD 20857		Kelley Biser	 	d. FAX No.	
2. PERIOD OF AGREEMENT		c. E mail:			
a. I ENDE OF CONSESSENT	FROM: October 1, 2006		тнкоисн: Sept	ember 30, 2007	
This agreement may be terminate FDA, FDA will retain title for any ed					
3. AUTHORITY (FDA)					
Economy Act approved June 30, 1932	·			•	
Section 301 of the Public Health Service	e Act (42 USC 241)	:			
Other (specify)	•			· .	
4. AUTHORITY (Other Agency)				•	
5. FDA FUNDING INFORMATION		·	· ·		•
•	76,800,00	76.800.0	0		· · · ·
5. FDA FUNDING INFORMATION Increase from \$	by \$76,800.00	to \$ 76,800.0	0		 .
increase from \$			0		· · · · · · · · · · · · · · · · · · ·
☑ Increase from \$	by \$	to \$	0		· · · · · · · · · · · · · · · · · · ·
☑ Increase from \$	by \$	to \$	0		<u> </u>
Increase from \$ Decrease from \$ 6. Administrative billing requirements will com	by \$ ply with GAO Policy and Procedure	to \$s, Title 7, Section 8.4			· · · · · · · · · · · · · · · · · · ·
Increase from \$	by \$	to \$s, Title 7, Section 8.4			· · · · · · · · · · · · · · · · · · ·
Increase from \$	by \$ ply with GAO Policy and Procedure	to \$s, Title 7, Section 8.4			
Increase from \$	by \$ ply with GAO Policy and Procedure ystem FDA ALC 75060099 Other A 0 - FDA Accounting (HFA-120) 5600	to \$s, Title 7, Section 8.4 gency ALC 0 Fishers Lane, Rockvi	lle, MD 20857		
Increase from \$	by \$ ply with GAO Policy and Procedure ystem FDA ALC 75060099 Other A 0 - FDA Accounting (HFA-120) 5600 DRMATION (This block must be con	to \$s, Title 7, Section 8.4 gency ALC 0 Fishers Lane, Rockvi	lle, MD 20857	1.)	
Increase from \$	by \$	to \$s, Title 7, Section 8.4 gency ALC 0 Fishers Lane, Rockvi mpleted if funding is be your agency.	lle, MD 20857	1.)	
Increase from \$	by \$	to \$s, Title 7, Section 8.4 gency ALC 0 Fishers Lane, Rockvi mpleted if funding is be your agency.	lle, MD 20857	L.)	
Increase from \$	by \$	to \$s, Title 7, Section 8.4 gency ALC 0 Fishers Lane, Rockvi mpleted if funding is be your agency.	lle, MD 20857	.,	
Decrease from \$ Decrease from \$ Administrative billing requirements will com PARTICIPATING AGENCY FUNDING INFI Note: a. Legal authority for the acquisition b. This action does not conflict with	by \$	to \$s, Title 7, Section 8.4 gency ALC 0 Fishers Lane, Rockvi mpleted if funding is be your agency.	lle, MD 20857	L)	
Decrease from \$	by \$	to \$s, Title 7, Section 8.4 gency ALC 0 Fishers Lane, Rockvi mpleted if funding is be your agency.	lle, MD 20857	.)	
Increase from \$	by \$	s, Title 7, Section 8.4 gency ALC O Fishers Lane, Rockvi impleted if funding is be your agency. sponsibility.	lle, MD 20857 ing provided to the FDA		
Decrease from \$	by \$	s, Title 7, Section 8.4 gency ALC O Fishers Lane, Rockvi mpleted if funding is be your agency. ponsibility.	Ile, MD 20857 ing provided to the FDA		
Decrease from \$	by \$	s, Title 7, Section 8.4 gency ALC O Fishers Lane, Rockvi impleted if funding is be your agency. sponsibility.	lle, MD 20857 ing provided to the FDA		
Decrease from \$	by \$	s, Title 7, Section 8.4 gency ALC O Fishers Lane, Rockvi mpleted if funding is be your agency. ponsibility.	Ile, MD 20857 ing provided to the FDA		
Decrease from \$	by \$	s, Title 7, Section 8.4 gency ALC O Fishers Lane, Rockvi impleted if funding is be your agency. sponsibility. 20. PARTICIPATIN NAME: Susan	Ile, MD 20857 ing provided to the FDA G AGENCY ACCEPTAL M. Panasik	yce wan M. J	
Decrease from \$	by \$	s, Title 7, Section 8.4 gency ALC O Fishers Lane, Rockvi impleted if funding is be your agency. sponsibility. 20. PARTICIPATIN NAME: Susan	Ile, MD 20857 ing provided to the FDA G AGENCY ACCEPTAL M. Panasik		
Increase from \$	by \$	s, Title 7, Section 8.4 gency ALC O Fishers Lane, Rockvi impleted if funding is be your agency. sponsibility. 20. PARTICIPATIN NAME: Susan	Ile, MD 20857 ing provided to the FDA G AGENCY ACCEPTAL M. Panasik	yce wan M. J	
Decrease from \$	by \$	s, Title 7, Section 8.4 gency ALC O Fishers Lane, Rockvi impleted if funding is be your agency. sponsibility. 20. PARTICIPATIN NAME: Susan	Ile, MD 20857 ing provided to the FDA G AGENCY ACCEPTAL M. Panasik	yce wan M. J	- Conac

INTERAGENCY AGREEMENT BETWEEN THE FOOD AND DRUG ADMINISTRATION (FDA) AND THE

OFFICE OF THE GENERAL COUNSEL (OGC) DEPARTMENT OF HEALTH AND HUMAN SERVICES

This agreement sets forth the terms under which the Food and Drug Administration (PDA) is to reimburse the Office of the General Counsel (OGC) for WESTLAW, LEXISNEXIS, and PACER usage. In addition, this agreement authorizes the transfer of funds to the OGC when certain economies can be realized through joint purchases of publications and subscriptions.

I. FURPOSE

The OGC will fund and manage WESTLAW and LEXISNEXIS contracts on behalf of the Office of the General Counsel Food and Drug Division (FDD). The FDA will transfer funds to cover FDD's portion of the charges for use of these online services. The charges will consist of two components: a proportion of OGC's fixed rate charges for FY 2007 for each service plus a reimbursement of any FDD usage not covered under the fixed rate agreements. Additional monies will fund FDD's use of the PACER system for tracking the status of court cases and provision of other services to the FDD library. Finally, FDA will reimburse OGC for any expenditures made for the FDD in order to obtain savings through joint purchases of publications and subscriptions.

II. PERIOD OF PERFORMANCE

This agreement covers the period October 1, 2006 to September 30, 2007.

III. AUTHORITY

This agreement is authorized by 31 U.S.C. 1535 (the Economy Act).

IV. FINANCIAL PROVISIONS

FDA will transfer the sum of Seventy Six Thousand Eight Hundred Dollars (\$76,800.00) to the OGC as follows:

- 1.) The sum of Seventy Four Thousand Three Hundred Dollars (\$74,300.00) will cover the FDD share of the fixed rate contracts with WESTLAW and LEXISNEXIS for FY 2007.
- 2.) The sum of Five Hundred Dollars (\$500.00) will be used for non-fixed rate usage. The OGC may request additional funds for non-fixed rate usage if usage exceeds this amount.
- 3.) The sum of Two Thousand Dollars (\$2,000.00) for OGC's projected PACER use by FDA personnel for the period of the agreement.

FDA agrees that the transfer of monies for online services and the library services will take place within thirty days of the date of the last signature affixed hereto.

Erom: FDA

To: OGC

	•	•	
Appropriation	7570600	Appropriation	7570120
CAN	7-6993830	CAN	7-1992313
Object Class	25309	Object Class	25.38
Amount	\$76,800.00	Amount	\$76,800.00
D&B Number	927645523	D&B Number	112463521
ALC	75-06-0099	ALC	75030030

APPROVAL AND ACCEPTANCE

Approved and accepted for FDA

Bir

Approved and accepted for OGC



DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration



1. IAG NO. (FDA)	2. TYPE OF AGREEMENT	Γ			3. MODIFICATION NO.
224-95-8003	New Mod	Admir	nistrative 1	No Cost Ext.	14
4. TITLE OF PROJECT				•	5. SECURITY CLAUSE APPLIES
Westlaw and LEXIS On-Line Legal Res	earch Services				Yes (See attached) No
6.DESCRIPTION OF WORK - ATTACHED				7. AMOUNT	
Unchanged from 04 - Attached				\$60,020.00	
8. NAME AND ADDRESS OF PARTICIPATING FED	ERAL AGENCY	9.	LIAISON TO PAF	RTICIPATING FEDI	FRAL AGENCY
OS/Office of the General Counsel	•	a. 1	Name 5054	M M. PANAS	IK b. Phone No. 202-619-0190
330 Independence Ave., SW, Room 700	E	<u> </u>	onald E. Wati E mail:	ts	(202) 690 - 7705 d. FAX No.
Washington, DC 20201		6. 1	_ 111011.		() -
10. NAME AND ADDRESS OF PARTICIPATING FE	DA UNIT			ARTICIPATING FDA	
FDA/Office of Chief Counsel 5600 Fishers Lane		,	Name nnette Hatton		b. Phone No. (301) 827 - 1156
Rockville, MD 20857			E mail:		d. FAX No.
		• .			-
12. PERIOD OF AGREEMENT FROM	M: October 1, 2005		THR	OUGH: Septen	nber 30, 2006
This agreement may be terminated by					
FDA, FDA will retain title for any equipr	ment procured under th	is agreemer	it, uniess otne	erwise jusuiled	in the statement of work.
13. AUTHORITY (FDA)	d-d-b04 11 C O 4505				
Economy Act approved June 30, 1932, as ar	-				
Section 301 of the Public Health Service Act	(42 USC 241)				
☐ Other (specify)			_		
14. AUTHORITY (Other Agency)	2 1520	~, ~ ~ ~ ~ ~ ~	a (MA)	112463	ca. (N. Sult)
1560/20 6-19923/ 15. FDA FUNDING INFORMATION	13 25.38	150300	30 (MC)	112 7000	02/(1985)
Increase	•				DUNS:927645523
from \$ 0.00	_ by \$ <u>60,020.00</u>		to \$ _60,0	20.00	_ EIN:530196965 ご
Decrease from					2006.6993830.253Q
\$	_ by \$		to \$		_ THC: 4415.026 TAPOGOOD
16. Administrative billing requirements will comply with	n GAO Policy and Procedures	s, Title 7, Section	n 8.4		
\boxtimes	·				•
Billing: X	_ IPAC system FDA ALC 75	060099 Other A	Agency ALC		
<u> </u>	SF 1080 - FDA Accounting	g (HFA-120) 560	00 Fishers Lane,	Rockville, MD 2085	77
17. PARTICIPATING AGENCY FUNDING INFORMA	TION (This block must be con	mpleted if fundi	na is beina provic	ded to the FDA.)	
Note: a. Legal authority for the acquisition of su	•	,		,	
 b. This action does not conflict with any of 	other agency's authority or res	sponsibility.			
18. PARTICIPATING AGENCY IS					* •
Required to sign	t required to sign	•			
			OIDATINO AGEN		
19. FDA ACCEPTANCE	<u> </u>	20. PARTI	CIPATING AGEN	NCY ACCEPTANCE	Math
NAME Tiche Conti		·	12011	WA - 6/1	~T.5
Usha Ganti ()	HANN -	NAME:	_ YON M	LI FOILM	///3
TITLE Chief Grants Management Officer	- FDΔ	T)T') ronh	or Office	of legal Reconvace
Ciner Grants Management Office	, IDA	TITLE:	J. EUI	, 0 /9 100	19 Negra 1, 10001 (63
DATE 100		DATE:	04/2	1/2006.	
-31100	<u>·</u> _	DATE:		-/	· · · · · · · · · · · · · · · · · · ·

INTERAGENCY AGREEMENT BETWEEN THE FOOD AND DRUG ADMINISTRATION (FDA) AND THE

OFFICE OF THE GENERAL COUNSEL (OGC) DEPARTMENT OF HEALTH AND HUMAN SERVICES

This agreement sets forth the terms under which the Food and Drug Administration (PDA) is to reimburse the Office of the General Counsel (OGC) for WESTLAW, LEXISNEXIS, and PACER usage. In addition, this agreement authorizes the transfer of funds to the OGC when certain economies can be realized through joint purchases of publications and subscriptions.

! . PURPOSE

The OGC will fund and manage WESTLAW and LEXISNEXIS contracts on behalf of the Office of the General Counsel Food and Drug Division (FDD). The FDA will transfer funds to cover FDD's portion of the charges for use of these online services. The charges will consist of two components: a proportion of OGC's fixed rate charges for FY 2006 for each service plus a reimbursement of any FDD usage not covered under the fixed rate agreements. Additional monies will fund FDD's use of the PACER system for tracking the status of court cases and provision of other services to the FDD library. Finally, FDA will reimburse OGC for any expenditures made for the FDD in order to obtain savings through joint purchases of publications and subscriptions.

II. PERIOD OF PERFORMANCE

This agreement covers the period October 1, 2005 to September 30, 2006.

III. AUTHORITY

This agreement is authorized by 31 U.S.C. 1535 (the Economy Act).

Section 301 of the Pubic Health Service Act (42 USC 241)

IV. FINANCIAL PROVISIONS

FDA will transfer the sum of Sixty Thousand Twenty Dollars (\$60,020.00) to the OGC as follows:

- 1.) The sum of Fifty-Seven Thousand Two Hundred Twenty Dollars (\$57,520.00) will cover the FDD share of the fixed rate contracts with WESTLAW and LEXISNEXIS for FY 2006.
- 2.) The sum of Five Hundred Dollars (\$500.00) will be used for non-fixed rate usage. The OGC may request additional funds for non-fixed rate usage if usage exceeds this amount.
- 3.) The sum of Two Thousand Dollars (\$2,000.00) for OGC's projected PACER use by FDA personnel for the period of the agreement.

FDA agrees that the transfer of monies for online services and the library services will take place within thirty days of the date of the last signature affixed hereto.

From: FDA

Appropriation Object Class

Amount D&B Number

ALC

EIN

7560600

6-6993830 253**@**Q \$60,020.00

927645523 75-06-0099 53-0196965

To: OGC

Appropriation

7560120 6-1992313 Object Class 25.38

Amount D&B Number

\$60,020.00 112463521 75030030

ALC

V. APPROVAL AND ACCEPTANCE

Approved and accepted for

By: Vala Cauli

Date: 6/1/06

Approved and accepted for the Office of the General Counsel

Donald E.

Director of Legal Resources

Date:



DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration



: NO (EDA)	2. TYPE OF AGREEMENT		3. MODIFICATION NO.
NO. (FDA) 224-95-8003		Administrative No Cost Ext.	13
	☐ New ☐ Mod ☐		S OF OUR PLANTS APPLIES
4. TITLE OF PROJECT Westlaw and LEXIS On-Line L	agal Dasaarah Sarrigas		5. SECURITY CLAUSE APPLIES
Weshaw and LEXIS On-Line L	tgai Research Services		Yes (See attached) No
6.DESCRIPTION OF WORK - ATTACHED		7. AMOUNT	
Unchanged from 04 - Attached		\$80,18	9.00
8, NAME AND ADDRESS OF PARTICIPA	TINO FEDERAL ACENOV	9. LIAISON TO PARTICIPATING	EEDERAL AGENCY
OS/Office of the General Couns		a. Name	b. Phone No.
330 Independence Ave., SW, Ro		Donald E. Watts	(202) 690 - 7705
Washington, DC 20201	, , , , , , , , , , , , , , , , , , ,	c. E mail:	d. FAX No.
•			(
10. NAME AND ADDRESS OF PARTICI	PATING FDA UNIT	11. LIAISON TO PARTICIPATING a. Name	b. Phone No.
FDA/Office of Chief Counsel		Annette Hatton	(301) 827 - 1156
5600 Fishers Lane		c. E mail:	d. FAX No.
Rockville, MD 20857	· '		() -
12. PERIOD OF AGREEMENT	FROM: October 1, 2004	THROUGH: Se	ptember 30, 2005
	- 1. Coloool 1, 2001	~	p
This agreement may be termin	nated by either party upon a thirty da	v advance written notice. If this	Agreement is funded by the
FDA, FDA will retain title for a	ny equipment procured under this ag	greement, unless otherwise justi	fied in the statement of work.
13. AUTHORITY (FDA)			
Economy Act approved June 30,	1022 as amanded by 21 H.S.C. 1525		
Section 301 of the Public Health	Service Act (42 USC 241)		
Other (specify)			
, AUTHORITY (Other Agency)			
)		*	
15. FDA FUNDING INFORMATION			
Increase			7550120 5-6993830
from \$ 0.00	by \$ 80,189.00	to \$ 80,189.00	25.3Q TAG:
			94151167AP05000
			DUNS:927645523
			ALC: 75060099
Decrease from	•	2.22	EIN: 530296965
\$	by \$	to \$ 0.00	
16. Administrative billing requirements will	comply with GAO Policy and Procedures, Title	e 7. Section 8.4	
⊠		•	
Billing: X	IPAC system FDA ALC 750600	99 Other Agency ALC	
	•		····
	SF 1080 - FDA Accounting (HF	A-120) 5600 Fishers Lane, Rockville, MD	20857
			-
	INFORMATION (This block must be complet uisition of supplies/services exists within your		4.)
, ,	ct with any other agency's authority or respons	-	•
18. PARTICIPATING AGENCY IS			
Required to sign	Not required to sign		
19. FDA ACCEPTANCE	1:	20. PARTICIPATING AGENCY ACCEPT	ANCE
NAME (Jose Anger	,	1 ke landle	•
Resemary Springer		NAME: JC WAPW	
			~ ~ ` ` ~ ` ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
Chief Grants Manageme	nt Officer, FDA	TITLE: DIRECTOR O	DF LEGAL RESOURCE
21.1.			,
DATE 8/L/S)		7/25/a	
. / /	8 1	DATE: 1/25/05	

DEPARTMENT OF

HEALTH AND HUMAN SERVICES

PURCHASE/SERVICE/STOCK REQUISITION

	0 1
REQUISITION NUMBER	
A05203	
OFFICE CODE/SYMBOL	***************************************
GCF-1	

BPA and Call No.

-			REQUEST FOR			·	
	ONTRACTS			SERVICE	STOCK ISS	UE 🔲	RENTAL/LEASE
	ING ORGANIZATION		CUSTODIAL AREA		DATE		OBJECT CLASS
	FFICEOF CHIEF COUNSEL -		0345 EXTENSION	·	07/01/0		25.3Q
	TE HATTON	•	301-827- 1156	APPROPRIATION 7540600 24200A/40			00A/40
DELIVER 1	го				CAN		
	OF CHIEF COUNSEL				4-6993	330-9-415	12
	03, GCF-1, PKLN BLDG SHERS LANE	•			DATE REC		
	ILLE, MD 20857						
7100113					UNIT		COST
ITEM NO.	(INCLUDE STOCK NL	DESCRIPTION IMBER, MODEL/PART	NO., ETC.)	QUANTITY REQUIRED	OF ISSUE	UNIT	TOTAL
	REQUEST FOR CONTINUA	TION OF REIM	BURSEABLE				
	INTERAGENCY AGREEME		•	·			\$79,290.00
	THE TOTAL TOTAL THE PARTY OF TH	AND THE PARTY OF THE					
		·		· .			
						,	
	FDA#: 224-95-8003						
	TITLE: WESTLAW AND LE	XIS On-Line Leg	gal Research	•			
	Services	•	,				٦.
	O.C. 25.3Q	•	·				
	PERIOD OF AGREEMENT:	10/01/03 THRU	9/30/04 .	1			
•							
	APPROVED:	Ko. Om.	10/EIL 1/3/04	1			
	PIRECTOR, O	FM	\overline{X}		1		
	76.0				1		
ļ						• .	
		•					
	•		1	1	. }		
	•				•		7
. 1			.		1		1
[4	A.		
			,	<i>-</i>			·
I certify that the	e property/services requested are required	FUNDS AVAILABLE	(Signature/Title)	DATE			
for Government or current asset	nt business, and are not available from excess	Qualte) SAKULUK	07/04/04	-	TOTAL	\$79,290.00
	BY (Stignature/Pitre) / The	MANAGEMEN DATE	NI ADVISOR	07/01/04		•	
1 llull	MENT ADVISOR		RECEIVING OFFICIAL -I			the "Quantity	
	APPROVAL (Signature/Title)*	07/01/04 DATE	Required" column above have been RECEIVING OFFICIAL (Signature)		is annotated,	· · · · · · · · · · · · · · · · · · ·	DATE
	· ···· (- · · · · · · · · · · · · · · ·		THEOLIVING OFFICIAL (BIgh	acarer cruej		İ	
APPROVED B	YYSignature Pittel 1	DATE	ORDER NO. (PO, DO, FEDS	TRIP ETC.			DDED DATE
F 754	126/1//		CABER NO. (FO, DO, FEDS	mir, £10,j			ORDER DATE
PRO/M	IANAGEMENT OFFICER (Signature)*	07/01/04 DATE	VOUCHER NO.	•			// /OUCHER DATE
V	, , , , , , , , , , , , , , , , , , , ,		TOSOILE NO.				
		//				/	//



DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Food and Drug Administration



1. IAG NO. (FDA)	2. TYPE OF AGREEMENT			3. MODIFICATION NO.
224-95-8003	New X Mod	Administrative	No Cost Ext.	12
4. TITLE OF PROJECT	L			
WESTLAW and LEXIS On-Line	Tegal Research	Services	•	
5. DESCRIPTION OF WORK - ATTACHED	cegar redearer	6. AMOUNT		
. Unchanged from 03 - Attache	- Ã	\$79,290	nn	
7. NAME AND ADDRESS OF PARTICIPATING FEDERA		LIAISON NAME:	.00	PHONE NO.
OS/Office of the General Co				(202) 690-7705
330 Independence Ave., Wash	nington, D.C.	Donald E.	Watts	(202) 030-1103
B. NAME AND ADDRESS OF PARTICIPATING FDA UN		LIAISON NAME:	·	PHONE NO.
FDA/Office of Chief Counsel		Annette Ha	tton ·	(301) 827-1156
Rockville, MD 20857		241116666 110	C,CO!1	
9. PERIOD OF AGREEMENT FROM:			THROUGH:	
10/01/	<u>′03</u>	09/30/0	04	e de Maria de Maria de Companya de Comp
This agreement may be	terminated by either p	arty upon a thirty	day advance wri	itten notice.
10. AUTHORITY (FDA)			·	
Economy Act approved June 30, 1932, as amen	•		**	
XXXXction 301 of the Public Health Service Act (42	USC 241)	•	•	
Other (specify) UTHORITY (Other Agency)				
OTHORIET (Other Agency)				
12. FDA FUNDING INFORMATION				
			7540600	
X Increase from 0 by 79 ,	290.00 to \$79	.290.00	24200A/40 4-6993830-	0_41510
			25.3Q	9-41312
Decrease fromby	to		FDA DUNS:	927645523
13. Administrative billing requirements will comply with G	AO Policy and Procedures,	Title 7, Section 8.4		
				•
XXBilling:OPAC system FI	DA ALC 75060099 Other Ag	ency ALC		
SF 1080 - FDA A	accounting (HFA-120) 5600	Fishers Lane, Rockvil	le, MD 20857	·
14. PARTICIPATING AGENCY FUNDING INFORMATIC				Ä)
7540120 75-03-0030				
41992313 25.38			•	•••
 a. Legal authority for the acquisition of supplies/sen b. This action does not conflict with any other agenc 				•
15. PARTICIPATING AGENCY IS				
Required to sign	Not required to sign			
16. FDA ACCEPTANCE		17. PARTICIPATIN	G AGENCY ACCEPTA	ANCE
			•	
******		NAME:	•	
ME:		INDIC.	_	
TMLE: Chief, Grants Mgmt. Offi	cer	TMLE: Direc	tor, Office	of <u>Legal</u> Resources
DATE:		DATE: 2		

INTERAGENCY AGREEMENT BETWEEN THE

FOOD AND DRUG ADMINISTRATION (FDA)

AND THE

OFFICE OF THE GENERAL COUNSEL (OGC)
DEPARTMENT OF HEALTH AND HUMAN SERVICES

This agreement sets forth the terms under which the FDA is to reimburse OGC for WESTLAW and LEXIS usage. In addition, this authorizes the transfer of funds to the OGC when certain economies can be realized through joint purchases of publications and subscriptions.

I. Purpose

* The OGC will fund and manage WESTLAW and LEXIS contracts in behalf of the Office of the General Counsel, Food and Drug Division (FDD). The FDA will transfer funds to cover FDD's portion of the charges for use of these online services. The charges will consist of two components: a proportion of OGCs fixed rate charges for FY 2004 for each service plus a reimbursement of any FDD usage not covered under the fixed rate agreements. Additional funds will fund FDD's use of the PACER system for tracking the status of court cases and to the FDD library. Finally, FDA will reimburse OGC for any expenditures made for the FDD in order to obtain savings through joint purchases of publications and subscriptions.

II. Period of Performance

This agreement covers the period October 1, 2003 to September 30, 2004.

III. Liaison Personnel

Annette Hatton
-Management Advisor
FDA/OCC
Room 6A03, Parklawn Bldg.
(301) 827-1156

Donald Watts
Executive Officer
OGC
Room 700E, HHH BLDG
(202) 690-7705

IV. Authority

This agreement is authorized by 31 U.S.C. 1535 (the Economy Act). FDA: Section 301 of the PHS Act 42 USC 241

V. Financial Provisions

FDA will transfer \$79,290 to the OGC as follows:

- \$78,212.65 will cover the FDD share of the fixed rate contracts with WESTLAW and LEXIS for FY 2004.

- \$1,076.95 for FDD portion of a bulk rate purchase of subscriptions to U.S. Law Week.

FDA agrees that the transfer of monies for online services and the library project will take place within thirty (30) days of the date of the last signature affixed hereto.

FROM: <u>FDA</u>	TO: OGC
Appropriation: 7540600 CAN : 46993830 Object Class : 25.3Q Amount : \$79,290 ALC : 75060099 DUNS : 927645523	Amount : \$79,290
VI. Approval and Acceptance	
Approved and accepted for FDA	Approved and accepted for the Office of the General Counsel
BY:	BY:
Date:	Date:





DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Food and Drug Administration



1. IAG NO. (FDA)	2. TYPE OF AGREEMEN	NT	3. MODIFICA	TION NO.	
224-95-8003	New XXX/od	Administrative		11	
4. TITLE OF PROJECT			<u></u>		
WESTLAW and LEXIS On-Line Leg	al Research Se	ervices	•		
5. DESCRIPTION OF WORK - ATTACHED		6. AMOUNT			
Unchanged from 02 - Attached		\$82,429.00			
7. NAME AND ADDRESS OF PARTICIPATING FEDERA	L AGENCY	LIAISON NAME:		PHONE NO.	
OS/Office of General Counsel 330 Independence Avenue, Wash	ington D.C	Donald E. Wat	.+.	(202)	690-7705
330 Independence fivence, wash	ington, b.c.	DOMAIG E. Wat	LS	(202)	690-7705
7. NAME AND ADDRESS OF PARTICIPATING FDA UNI FDA/Office of Chief Counsel	T	LIAISON NAME:		PHONE NO.	
5600 Fishers Lane		Annette Hatto	n	(301)	827-1156
Rockville, MD 20857				(501)	027 1130
9. PERIOD OF AGREEMENT FROM:			onghi:		
10/01	/02 ·	9/	30/03		
This agreement may be	terminated by either	party upon a thirty day a	dvance writ	ten notice	
10. AUTHORITY (FDA).					
Economy Act approved June 30, 1932, as amend	•				
XXXXection 301 of the Public Health Service Act (42 t	JSC 241) ·				•
Other (specify)					
Total (one Agency)				j	
12. FUA FUNDING INFORMATION					
increase from o by 80.429 to	2,469.00	753060	00	/ OO = 1	8 7 0
Decrease frombyto	- · · · · · · · · · · · · · · · · · · ·	25.30	5 -	6443	830
Administrative billing requir	ements will comply with		res. Title 7. S	ection 8.4	9-41576
OPAC system FDA ALC 750	• •	•	,,		
SF 1080 - FDA Accounting (FDA DU	JNS 9276	45523
13. PARTICIPATING AGENCY FUNDING INFORMATION	•				
7530120 3- 1990580	25.38	15030030	i		
a. Legal authority for the acquisition of supplies/service	es exists within your agend	cy.			•
b. This action does not conflict with any other agency's	authority or responsibility	•			
14. PARTICIPATING AGENCY IS				•	
XXXX Aequired to sign					\
Not required to sign 5. FDA ACCEPTANCE	Tr.	de participativo desve			
5. FUN ACCEPTANCE		15. PARTICIPATING AGENC	Y ACCEPTAN	GE J	
100		1 14	Line Al	la)	
IAME: JUNE JUNE	1	NAME:	was	~	
Peggy L. Jones					
Chief Grants Mgmt Officer	1.	TITLE: Donald E. Wa	atts Page		Office.
		THEE: DONALD LA THE	ACCO, 120		· OTTICEL
		AG/A	Planne	1	••
A1 8/20/23		DATE: <u>VO/010</u>	10000		
원 DA 3443 (7/96)					·
DO 0770 (1180)					EF

INTERAGENCY AGREEMENT BETWEEN THE FOOD AND DRUG ADMINISTRATION (FDA) AND THE

OFFICE OF THE GENERAL COUNSEL (OGC)
DEPARTMENT OF HEALTH AND HUMAN SERVICES

This agreement sets forth the terms under which the FDA is to reimburse OGC for WESTLAW and LEXIS usage. In addition, this authorizes the transfer of funds to the OGC when certain economies can be realized through joint purchases of publications and subscriptions.

I. Purpose

The OGC will fund and manage WESTLAW and LEXIS contracts in behalf of the Office of the General Counsel Food and Drug Division (FDD). The FDA will transfer funds to cover FDD's portion of the charges for use of these online services. The charges will consist of two components: a proportion of OGC's fixed rate charges for each service plus a reimbursement of any FDD usage not covered under the fixed rate agreements. Additional funds will fund FDD's use of the PACER system for tracking the status of court cases and a FDD library improvement project. Finally, FDA will reimburse OGC for any expenditures made for the FDD in order to obtain savings through joint purchases of publications and subscriptions.

II. Period of Performance

This agreement is for an indefinite period, but parties to this agreement will make annual amendments to section V, Financial Provisions, for funds certification to cover the funding arrangements to cover the normal fiscal year of October 1 of one year to September 30 of the following year.

IV. Authority

This agreement is authorized by 31 U.S.C. 1535 (the Economy Act).

V. Financial Provisions

In FY 2003, FDA will transfer \$82,429 to the OGC as follows:

\$78,923 will cover the FDD share of the fixed rate contracts with WESTLAW and LEXIS.

\$2,500 will be used to cover any non-fixed rate usage. The OGC may have to request additional funds for this type of use if it becomes substantial.

IAG, OGC and FDA

In addition, the FDD's portion of any subscription or publication joint purchases will charged back as accrued. It should not exceed \$1006 for the year.

From: FDA

Appropriation: 7530600

CAN: 36993830

Object Class: 25.3Q

Amount: \$82,429

ALC: 750 60099

DUNS: 927645523 VI. Approval and Acceptance

Approved and accepted for

the FDA

Peggy L. Jones Chief Grants Mgmt Officer

Food and Drug Administration

To: OGC

Appropriation: 7530120

CAN: 3-1992313

Object Class: 25.39

Amount: \$82,429 ALC: 75-03-0030 DUNS: 112463521

Approved and accepted for Office of the General

Counsel

Director, Office of Legal

Resources